ReEmerge Raises $37 Million Series A Funding, Will Test A Therapy For Chronic Cognitive Impairment Caused By Brain Injuries

ReEmerge, Inc. (ReEmerge) raised $37 million in Series A funding and launched from stealth. The company plans to use the funding to support an upcoming clinical study that will evaluate ReEmerge's proprietary Cognitive Network Restoration Therapy (CNRT) in its first clinical indication, traumatic brain injury (TBI). The company will also invest in technology development, expanding clinical and regulatory operations, and preparing the platform for future indications.

U.S. Venture Partners (USVP) and Santé co-led the round, with participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures. Jonathan Root, M.D., General . . .